Medpace (NASDAQ:MEDP) General Counsel Sells $7,357,050.00 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) General Counsel Stephen Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Medpace Stock Up 1.0%

Medpace stock traded up $4.36 during mid-day trading on Monday, reaching $451.47. 251,185 shares of the company’s stock were exchanged, compared to its average volume of 367,563. Medpace Holdings, Inc. has a twelve month low of $291.28 and a twelve month high of $628.92. The company has a market cap of $12.89 billion, a P/E ratio of 28.38, a P/E/G ratio of 2.27 and a beta of 1.18. The company has a fifty day moving average of $457.47 and a 200-day moving average of $513.36.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company’s quarterly revenue was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on MEDP shares. Robert W. Baird reduced their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. BMO Capital Markets cut their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Royal Bank Of Canada decreased their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Finally, Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $467.08.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Optiver Holding B.V. acquired a new position in Medpace in the third quarter valued at $27,000. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Medpace during the fourth quarter worth about $30,000. Elyxium Wealth LLC purchased a new stake in shares of Medpace in the 4th quarter valued at about $30,000. Quarry LP purchased a new stake in shares of Medpace in the 3rd quarter valued at about $35,000. Finally, Bayban acquired a new stake in shares of Medpace in the 4th quarter valued at about $44,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.